Sialic Acid Binding Ig-like Lectin 3
"Sialic Acid Binding Ig-like Lectin 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 67-kDa sialic acid binding lectin that is specific for MYELOID CELLS and MONOCYTE-MACROPHAGE PRECURSOR CELLS. This protein is the smallest siglec subtype and contains a single immunoglobulin C2-set domain. It may play a role in intracellular signaling via its interaction with SHP-1 PROTEIN-TYROSINE PHOSPHATASE and SHP-2 PROTEIN-TYROSINE PHOSPHATASE.
| Descriptor ID |
D063268
|
| MeSH Number(s) |
D12.776.503.921.400 D23.050.301.264.900.565 D23.101.100.900.565
|
| Concept/Terms |
Sialic Acid Binding Ig-like Lectin 3- Sialic Acid Binding Ig-like Lectin 3
- Sialic Acid Binding Ig like Lectin 3
- CD33 Antigens
- Siglec-3
- CD33 Antigen
- Antigen, CD33
- Glycoprotein gp67
- gp67, Glycoprotein
- Antigens, CD33
|
Below are MeSH descriptors whose meaning is more general than "Sialic Acid Binding Ig-like Lectin 3".
Below are MeSH descriptors whose meaning is more specific than "Sialic Acid Binding Ig-like Lectin 3".
This graph shows the total number of publications written about "Sialic Acid Binding Ig-like Lectin 3" by people in this website by year, and whether "Sialic Acid Binding Ig-like Lectin 3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sialic Acid Binding Ig-like Lectin 3" by people in Profiles.
-
The value of immunohistochemistry for CD14, CD123, CD33, myeloperoxidase and CD68R in the diagnosis of acute and chronic myelomonocytic leukaemias. Histopathology. 2012 May; 60(6):933-42.
-
G-CSF-mobilized CD34+ cells cultured in interleukin-2 and stem cell factor generate a phenotypically novel monocyte. J Leukoc Biol. 2004 Dec; 76(6):1214-9.
-
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res. 2003 Oct; 27(10):893-7.
-
Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol. 2002 Dec; 50(6):497-500.
-
Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol. 2002 Oct; 118(4):560-6.
-
Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy. Haematologica. 2002 Oct; 87(10):1114-6.
-
Precursor T-cell acute lymphoblastic leukemia in adults: age-related immunophenotypic, cytogenetic, and molecular subsets. Am J Clin Pathol. 2002 Feb; 117(2):252-8.
-
t(12;17)(p13;q21) in early pre-B acute lymphoid leukemia. Leukemia. 1992 Apr; 6(4):251-5.